Angle PLC Notice of Interim Results (1562N)
January 27 2016 - 5:43AM
UK Regulatory
TIDMAGL
RNS Number : 1562N
Angle PLC
27 January 2016
For Immediate Release 27 January 2016
ANGLE plc
("ANGLE" or "the Company")
Notice of Interim Results
ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech
company, will announce its interim results for the six months ended
31 October 2015 on Thursday 28 January 2016.
A meeting for analysts will be held at 10:00am on 28 January
2016 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate
Street, London EC1A 4HD.
To listen to the live webcast of the analyst meeting, please
register at
http://www.angleplc.com/investor-information/corporate-presentations/
for details.
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher
Golden (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in the United States, Canada, China and Australia
and three extensive families of patents are being progressed
worldwide. The system is based on a microfluidic device that
captures cells based on a combination of their size and
compressibility. The Parsortix system is established with strong
positive evaluations from leading cancer research centres and is
working with these cancer centres to demonstrate key applications.
Parsortix has a CE Mark for Europe and FDA authorisation is in
process for the United States.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi $billion clinical market. The Parsortix system
is designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market. The product is on
the market and being sold for research use and work is progressing
towards approvals for clinical use to permit clinical sales of the
system.
ANGLE is strongly focused on establishing the use of the
Parsortix system in clinical practice. To achieve this, ANGLE has
established formal collaborations with world-class cancer centres.
These Key Opinion Leaders are working to identify applications with
medical utility (clear benefit to patients), and to secure clinical
data that demonstrates that utility in patient studies. ANGLE
believes this is the optimal approach for unlocking the
multi-billion dollar worldwide market available to the Company and
its potential strategic partners. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFVILAIDFIR
(END) Dow Jones Newswires
January 27, 2016 05:43 ET (10:43 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024